Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.49 |
| ▸ | BCHE | P06276 | 8/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938403 | 0.91 | PKM (0.55) | ACHEBCHELPAR1LPAR5ATM | |
| SCHEMBL14938410 | 0.89 | NR4A1 (0.56) | ACHEBCHE | |
| SCHEMBL3039207 | 0.83 | MEN1 (0.59) | ACHEBCHELPAR1LPAR5BCL2 | |
| SCHEMBL3040571 | 0.81 | MEN1 (0.63) | ACHEBCHEBCL2 | |
| SCHEMBL14938401 | 0.79 | MRGPRX4 (0.60) | ACHE | |
| SCHEMBL3032034 | 0.79 | LTA4H (0.59) | ACHEBCHELPAR1LPAR5BCL2 | |
| SCHEMBL4327125 | 0.75 | PKM (0.73) | — | |
| SCHEMBL16062223 | 0.75 | ACHE (0.64) | ACHEBCHE | |
| SCHEMBL14569771 | 0.75 | TSHR (0.69) | ACHEBCHEATM | |
| SCHEMBL3038720 | 0.74 | PKM (0.67) | ACHEBCHEATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | ACHE 328/4885BCHE 892/4885LPAR1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.